Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

doi:10.1158/1078-0432.CCR-17-1767

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2018

Erbe Amy K, Wang Wei, Carmichael Lakeesha, Kim KyungMann, Mendonça Eneida A, Song Yiqiang, Hess Dustin, Reville Patrick K, London Wendy B, Naranjo Arlene, Hank Jacquelyn A, Diccianni Mitchell B, Reisfeld Ralph A, Gillies Stephen D, Matthay Katherine K, Cohn Susan L, Hogarty Michael D, Maris John M, Park Julie R, Ozkaynak M Fevzi, Gilman Andrew L, Yu Alice L, Sondel Paul M

Abstract excerpt

Purpose: In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy regimen of dinutuximab, GM-CSF, IL2, and isotretinoin compared with treatment with isotretinoin alone. Dinutuximab, a chimeric anti-GD2 monoclonal antibody, acts in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Immunotherapy

Share to Ligands

Share to Neuroblastoma

Share to Receptors, KIR

Share to Receptors, KIR2DL1

Share to Receptors, KIR3DL1

Source

Open in PubMed Open full text

Identifiers

PMID: 28972044
DOI: 10.1158/1078-0432.CCR-17-1767
PMCID: PMC5754221

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.PMID 28972044Read ↗

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.Semantic proximity Read ↗

KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.Semantic proximity Read ↗

Clinical Impact of KIR2DS3 and KIR2DL3 Genes in Neuroblastoma Patients.Semantic proximity Read ↗

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.Semantic proximity Read ↗

Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.Semantic proximity Read ↗

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion TrialSemantic proximity Read ↗

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survivalSemantic proximity Read ↗

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read ↗

Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.Semantic proximity Read ↗

Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients.Semantic proximity Read ↗

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.Semantic proximity Read ↗

Natural killer cell educating KIR/HLA combinations impact survival in anti-PD-L1 treated cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.